Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab

mAbs

Volumn 8, Issue 1, 2016, Pages 99-112

  Courtois, Fabienne ^a   Agrawal, Neeraj J ^a   Lauer, Timothy M ^a   Trout, Bernhardt L ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Aggregation; Bevacizumab; Biobetter; Glycosylation; Monoclonal antibody; Protein engineering; Spatial aggregation propensity; Stability

Indexed keywords

ASPARTIC ACID; BEVACIZUMAB; CARBOHYDRATE; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; PROLINE; VASCULOTROPIN A; PROTEIN AGGREGATE;

AMINO ACID SUBSTITUTION; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HEAT STRESS; POINT MUTATION; PROTEIN AGGREGATION; PROTEIN ENGINEERING; BIOSYNTHESIS; CELL LINE; CHEMISTRY; GENETICS; HUMAN; PROCEDURES; PROTEIN MOTIF;

AMINO ACID MOTIFS; BEVACIZUMAB; CELL LINE; HUMANS; PROTEIN AGGREGATES; PROTEIN ENGINEERING;

EID: 84964556388     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1112477     Document Type: Article

References (78)

1. Aggarwal RS. What's fueling the biotech engine-2012 to 2013. Nat Biotechnol 2014; 32:32-9; PMID:24406926; http://dx.doi.org/10.1038/nbt.2794
2. Joshi V, Shivach T, Kumar V, Yadav N, Rathore A. Avoiding antibody aggregation during processing: establishing hold times. Biotechnol J. 2014; 9:1195-205; PMID:24753430; http://dx.doi.org/10.1002/biot.201400052
3. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: Influence of aggregation. J Immunotoxicol 2014; 11:99-109; PMID:23919460; http://dx.doi.org/10.3109/1547691X.2013.821564
4. Rosenberg AS. Effects of protein aggregates: an immunologic perspective, AAPS J 2006; 8:E501-E507; http://dx.doi.org/10.1208/aapsj080359
5. Vázquez-Rey M, Lang DA. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 2011; 108:1494-508; PMID:Can't; http://dx.doi.org/10.1002/bit.23155
6. Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009; 20:708-14; PMID:19880308; http://dx.doi.org/10.1016/j. copbio.2009.10.006
7. Roque C, Sheung A, Rahman N, Ausar SF. Effect of polyethylene glycol conjugation on conformational and colloidal stability of a monoclonal antibody antigenbinding fragment (Fab'). Mol Pharm 2015; 12:562-75; PMID:25548945; http://dx.doi.org/10.1021/mp500658w
8. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnology Journal 2011; 6:38-44; PMID:20949542; http://dx.doi.org/10.1002/biot. 201000091
9. Perchiacca JM, Tessier PM. Engineering Aggregation-Resistant Antibodies. Annu Rev Chem Biomol Eng 2012; 3:263-86; PMID:22468604; http://dx.doi.org/10.1146/annurev-chembioeng-062011-081052
10. Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm Sci. 2011; 100:5081-95; PMID:21789769
11. Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: Influence of aggregation; K.D. J Immunotoxicol 2014; 11:99-109; PMID:23919460; http://dx.doi.org/10.3109/1547691X.2013.821564
12. Castillo V, Graña-Montes R, Sabate R, Ventura S. Prediction of the aggregation propensity of proteins from the primary sequence: aggregation properties of proteomes. Biotechnol J 2011. 6:674-85; PMID:21538897; http://dx.doi.org/10.1002/biot. 201000331
13. Wang X, Das TK, Singh SK, Kumar S. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. mAbs 2009; 1:254-67; PMID:20065649; http://dx.doi.org/10.4161/mabs.1.3.8035
14. Chennamsetty N, Voyonov V, Kayser V, Helk B, Trout BL. Design of Therapeutic proteins with enhanced stability. Proc Nat Acad Sci 2009. 106:11937-42; PMID:19571001; http://dx.doi.org/10.1073/pnas.0904191106
15. Chennamsetty N, Helk B, Voyonov V, Kayser V, Trout BL. Aggregation-Prone motifs in Human Immunoglobulin G. J Mol Biol 2009; 391:404-413; PMID:19527731; http://dx.doi.org/10.1016/j.jmb. 2009.06.028
16. Voynov V, Chennamsetty N, Kayser V, Helk B, Trout BL. Predictive tools for stabilization of therapeutic proteins. mAbs 2009; 1:580-1; PMID:20068399; http://dx.doi.org/10.4161/mabs.1.6.9773
17. Voynov V, Chennamsetty N, Kayser V, Wallny HJ, Helk B, Trout BL. Design and application of antibody cysteine variants. Bioconjugate Chemistry 2010; 21; 385-92; PMID:20092294; http://dx.doi.org/10.1021/bc900509s
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691
19. Los M, Roodhart JML, Voest EE. Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. Oncologist. 2007; 12:443-50; PMID:17470687; http://dx.doi.org/10.1634/theoncologist.12-4-443
20. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2009; 20:158-65; PMID:19417570; http://dx.doi.org/10.1097/ICU.0b013e32832d25b3
21. Paul M, Lahlou A, Carvalho M, Blanchet B, Astier A. Thermal stability of two monoclonal antibodies: cetuximab and bevacizumab. Eur J Oncol Pharm 2008; 2:37
22. Oliva A, Llabrés M, Fariña JB. Capability measurement of size-exclusion chromatography with a light-scattering detection method in a stability study of bevacizumab using the process capability indices. J Chromatogr A 2014; 1353:89-98; PMID:24786652; http://dx.doi. org/10.1016/j.chroma.2014.04.027
23. Cromwell M, Gazzano-Santoro H. Protein Aggregation and Potency, Genentech, Inc, IIR Conference on Impurities of Biomolecules, 2006 Nov 7; San Francisco, CA. Available from: www.iirusa.com/upload/wys iwyg/P1198_Images/IIR_P1198_Cromwell.pdf
24. Latypov RF, Hogan S, Lau H, Gadgil H, Liu D. Elucidation of Acid-induced Unfolding and Aggregation of Human Immunoglobulin IgG1 and IgG2 Fc. J Biol Chem 2012; 287:1381-96; PMID:22084250; http://dx.doi.org/10.1074/jbc.M111.297697
25. Wang X, Kumar S, Buck PM, Singh SK. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: Observations from molecular dynamics Simulations. Proteins 2013; 81:443-60; PMID:23065923; http://dx.doi.org/10.1002/prot.24202
26. Li CH, Narhi LO, Wen J, Dimitrova M, Wen Z, Li J, Pollastrini J, Nguyen X, Tsuruda T, Jiang Y. Effect of pH, Temperature, and Salt on the Stability of Escherichia coli-and Chinese Hamster Ovary Cell-Derived IgG1 Fc. Biochemistry 2012; 51:10056-65; PMID:23078371; http://dx.doi.org/10.1021/bi300702e
27. Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. mAbs 2011; 3:568-76; PMID:22123061; http://dx.doi.org/10.4161/mabs.3.6.17922
28. Sinclair AM, Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 2005; 94:1626-35; PMID:15959882; http://dx.doi.org/10.1002/jps.20319
29. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, Walus L, Eldredge J, Capili A, Mi S, Graff C, Garber E. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Science 2010; 19:954-66; PMID:20198683
30. Voynov V, Chennamsetty N, Kayser V, Helk B, Forrer K, Zhang H, Fritsch C, Heine H, Trout BL. Dynamic fluctuations of protein-carbohydrate interactions promote protein aggregation. PLoS One 2009; 4:e8425; PMID:20037630; http://dx.doi.org/10.1371/journal. pone.0008425
31. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B. 2010; 114:6614-24; PMID:20411962; http://dx.doi.org/10.1021/jp911706q
32. Courtois F, Schneider CP, Agrawal NJ, Trout BL. Rational design of biobetters with enhanced stability. J Pharm Sci 2015; 104:2433-40; PMID:26096711; http://dx.doi.org/10.1002/jps.24520
33. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of protein binding regions. Proteins 2011; 79:888-97; PMID:21287620; http://dx.doi.org/10.1002/prot.22926
34. Westermaier Y, Veurink M, Riis-Johannessen T, Guinchard S, Gurny R, Scapozza L. Identification of aggregation breakers for bevacizumab (Avastin©) selfassociation through similarity searching and interaction studies. European Journal of Pharmaceutics and Biopharmaceutics 2013; 85:773-80; PMID:23665445; http://dx.doi.org/10.1016/j.ejpb.2013.04.012
35. Veurink M, Westermaier Y, Gurny R, Scapozza L. Breaking the aggregation of the monoclonal antibody bevacizumab (Avastin©) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation, Pharm Res 2013; 30:1176-87; PMID:23412914; http://dx.doi.org/10.1007/s11095-012-0955-6
36. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc MP, Watier H. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev in Oncol Hematol 2007; 64:210-25; http://dx.doi.org/10.1016/j.critrevonc.2007.04.011
37. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998; 6:1153-67; PMID:9753694; http://dx.doi.org/10.1016/S0969-2126(98)00116-6
38. Kaja S, Hilgenberg JD, Everett E, Olitsky SE, Gossage J, Koulen P. Effects of dilution and prolonged storage with preservative in a polyethylene container on Bevacizumab (AvastinTM) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. Hum Antibodies 2011; 20:95-101; PMID:22129679
39. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A 2012; 109:10879-84; PMID:22745168; http://dx.doi.org/10.1073/pnas.1202866109
40. Bakri SJ, Snyder MR, Pulido JS, McCannel CA, Weiss WT, Singh RJ. Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 2006; 26:519-22; PMID:16770257; http://dx. doi.org/10.1097/01.iae.0000225354.92444.7a
41. Paul M, Vieillard V, Roumi E, Cauvin A, Despiau MC, Laurent M, Astier A. Long-term stability of bevacizumab repackaged in 1 mL polypropylene syringes for intravitreal administration. A. Ann Pharm Fr 2012; 70:139-54; PMID:22655582; http://dx.doi.org/10.1016/j.pharma.2012.03.006
42. Liu L, Ammar DA, Ross LA, Mandava N, Kahook NY, Carpen-ter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophtalmol Vis Sci 2011; 52:1023-34; http://dx.doi.org/10.1167/iovs.10-6431
43. Veurink M, Stella C, Tabatabay C, Pournaras CJ, Gurny R. Association of ranibizumab (Lucentis©) or bevacizumab (Avastin©) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment. Eur J Pharm Biopharm 2011; 78:271-7; PMID:21172437; http://dx. doi.org/10.1016/j.ejpb.2010.12.018
44. Zhang A, Singh SK, Michael R, Shirts MR, Kumar S, Fernandez EJ. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 2012; 29:236-250; PMID:21805212; http://dx.doi. org/10.1007/s11095-011-0538-y
45. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies. J Pharm Sci. 2008; 97:1414-26; PMID:17721938; http://dx.doi.org/10.1002/jps.21104
46. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15: 171-85; PMID:22302382; http://dx.doi.org/10.1007/s10456-011-9249-6
47. Yu Y, Lee P, Ke Y, Zhang Y, Yu Q, Lee J, Li M, Song J, Chen J, Dai J, Do Couto FJ, An Z, Zhu W, Yu GL. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. Plosone 2010; 5:e9072; http://dx.doi. org/10.1371/journal.pone.0009072
48. Jenkins N. Modifications of therapeutic proteins: challenges and prospects. Cytotechnology 2007; 53:121-5; PMID:19003198
49. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins. Annu Rev Immunol 2007; 25:21-50; PMID:17029568
50. Lee CC, Perchiacca JM, Peter M. Tessier PM. Toward aggregation-resistant antibodies by design. Trends Biotechnol 2013; 31:612-20; PMID:23932102
51. Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall'Acqua W, Minter R, Jermutus L, Bedian V. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. mAbs 2013; 5:255-62; PMID:23412563
52. Olsson MHM, Sondergard CR, Rostkowski M, Jensen JH. Consistent Treatment of Internal and Surface Residues in Empirical pKa predictions. J Chem Theory Comput. 2011; 7:525-37
53. Perchiacca JM, Lee CC, Tessier PM. Optimal charged mutations in the complementarity determining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. Protein Engineering, Design & Selection 2014; 27:29-39
54. Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 2010; 23:643-51; PMID:20543007
55. Hristodorov D, Fischer R, Linden L. With or Without Sugar? (A)glycosylation of Therapeutic Antibodies. Mol Biotechnol 2013; 54:1056-68; PMID:23097175
56. Hari, SB, Lau H, Razinkov VI, Chen S, Latypov RF. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. Biochemistry 2010; 49:9328-38; PMID:20843079
57. Hristodorov D, Fischer R, Joerissen H, Müller-Tiemann B, Apeler H, Linden L. Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies. Mol Biotechnol 2013; 53:326-35; PMID:22427250
58. Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, Rudd PM, Woof JM, Dwek RA. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions. J Biol Chem 1998; 273:2260-72; PMID:9442070
59. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009; 8:226-234; PMID:19247305
60. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364:8-18; PMID:17362871
61. Sanchez-Ruiz JM. Theoretical analysis of Lumry-Eyring models in differential scanning calorimetry. Biophys J 1992; 61:921-35; PMID:19431826
62. Calis JJA, Maybeno M, Greenbaum JA, Weiskopf D, De Silva AD, Sette A, Kesmir C, Peters B. Properties of MHC class I presented peptides that enhance immunogenicity. PloS Comp Biol 2013; 9:e1003266
63. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett 1990; 276:172-4; PMID:1702393; http://dx.doi.org/10.1016/0014-5793(90)80535-Q
64. Trout BL, Schneider CP, Agrawal NJ. Her2-and vegfa-binding proteins with enhanced stability. U.S. Patent Application No. 61/706240. 2013.
65. Trout BL, Schneider CP, Agrawal NJ. Cd20-and egfrbinding proteins enhanced stability. U.S. Patent Application No. 61/706242. 2013.
66. Lavoisier A, Schlaeppi JM. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection. mAbs 2015; 7:77-83; PMID:25514497; http://dx.doi.org/10.4161/19420862.2014.985544
67. Yamniuk AP, Ditto N, Patel M, Dai J, Sejwal P, Stetsko P, Doyle ML. Application of a kosmotropebased solubility assay to multiple protein therapeutic classes indicates broad use as a high-throughput screen for protein therapeutic aggregation propensity. J Pharm Sci 2013; 102:2424-39; PMID:23712759; http://dx.doi.org/10.1002/jps. 23618
68. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 2012; 101:102-15; PMID:21935950; http://dx.doi.org/10.1002/jps. 22758
69. Obrezanova O, Arnell A, de la Cuesta RG, Berthelot ME, Gallagher TR, Zurdo J, Stallwood Y. Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs 2015; 7:352-63; PMID:25760769; http://dx.doi.org/10.1080/19420862.2015.1007828
70. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14:33-8; PMID:8744570; http://dx.doi.org/10.1016/0263-7855(96)00018-5
71. Woods Group. GLYCAM Web; web tool. Complex Carbohydrate Research Center, University of Georgia, Athens, GA; 2005; last accessed 2015 June 5. Available from www.glycam.org
72. Case, DA, Darden TA, Cheatham TE III, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM, et al. AMBER 12; University of California, San Fransisco, 2012.
73. Kirschner KN, Yongye AB, Tschampel SM, Gonzalez-Outeiriño J, Daniels CR, Foley BL, Woods RJ. GLYCAM06: A generalizable biomolecular force field. Carbohydrates. J Comput Chem 2008; 29:622-55; PMID:17849372; http://dx.doi.org/10.1002/jcc. 20820
74. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79:926-35; http://dx.doi.org/10.1063/1.445869
75. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984; 81:3684-90; http://dx.doi.org/10.1063/1.448118
76. Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation 2008; 4:435-47; http://dx.doi.org/10.1021/ct700301q
77. Agrawal NJ, Helk B, Trout BL. A computational tool to predict the evolutionarily conserved protein-protein interaction hot-spot residues from the structure of the unbound protein. FEBS Letters 2014; 588:326-33; PMID:24239538; http://dx.doi.org/10.1016/j. febslet.2013.11.004
78. Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res 2013; 41:34-40; http://dx.doi. org/10.1093/nar/gkt382